Oncogenex Pharma drug fails in late-stage prostate cancer trial
Oncogenex Pharmaceuticals Inc. shares (Nasdaq:OGXI) fell 60.3 percent after the company and its partner, Teva Pharmaceutical Industries Ltd., reported that their experimental prostate cancer therapy, custirsen, failed to perform better than standard chemotherapy in a pivotal trial.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter